<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02790138</url>
  </required_header>
  <id_info>
    <org_study_id>Vedolizumab-4004</org_study_id>
    <secondary_id>U1111-1171-0918</secondary_id>
    <secondary_id>2015-003472-78</secondary_id>
    <nct_id>NCT02790138</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis</brief_title>
  <acronym>EARNEST</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of vedolizumab intravenous (IV) and&#xD;
      placebo in terms of the percentage of participants with chronic or recurrent pouchitis&#xD;
      achieving clinically relevant remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vedolizumab is being tested to treat people who have chronic pouchitis. This study will look&#xD;
      at the healing of inflammation of ileal pouch in people who take vedolizumab as compared to&#xD;
      those receiving a matching placebo. The study will enroll approximately 110 patients.&#xD;
      Participants will be randomly assigned to one of the two treatment groups-which will remain&#xD;
      undisclosed to the patient and study doctor during the study (unless there is an urgent&#xD;
      medical need):&#xD;
&#xD;
        -  Vedolizumab 300 mg IV&#xD;
&#xD;
        -  Placebo IV&#xD;
&#xD;
      All participants will receive an intravenous infusion at Day 1, Weeks 2, 6, 14, 22, and 30&#xD;
      along with concomitant antibiotic treatment with ciprofloxacin 500 mg twice daily through&#xD;
      Week 4.&#xD;
&#xD;
      This multicenter trial will be conducted in North America and Europe. The overall time to&#xD;
      participate in treatment and efficacy assessment of this study is 34 weeks. Participants will&#xD;
      make multiple visits to the clinic, plus a final visit 18 weeks after the last dose of study&#xD;
      drug for a safety follow-up assessment (up to Week 48). Participants will also participate in&#xD;
      a long-term follow-up, by phone after the last dose of study drug up to Week 56.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2016</start_date>
  <completion_date type="Actual">February 2, 2021</completion_date>
  <primary_completion_date type="Actual">June 11, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Chronic or Recurrent Pouchitis Achieving Clinically Relevant Remission at Week 14</measure>
    <time_frame>Week 14</time_frame>
    <description>Clinically relevant remission is defined as modified Pouchitis Disease Activity Index (mPDAI) score &lt;5 and a reduction of mPDAI score by ≥2 points from Baseline. The 12-point mPDAI score is calculated from two 6-point subscales: 1) Clinical Symptoms: Stool Frequency (0=usual to postoperative stool frequency to 2=three or more stools/day&gt;postoperative usual); Rectal bleeding (0=None or rare to 1=Present daily); Fecal urgency or abdominal cramps (0=None to 2=Usual), Fever [temperature &gt;37.8 degrees C] (0=Absent and 1=Present) for a clinical symptoms subscore of 0 (best) to 6 (worse); 2) Endoscopic Inflammation Findings: Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates and Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0 (best) to 6 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Chronic or Recurrent Pouchitis Achieving Clinically Relevant Remission at Week 34</measure>
    <time_frame>Week 34</time_frame>
    <description>Clinically relevant remission is defined as mPDAI score &lt;5 and a reduction of mPDAI score by ≥2 points from Baseline. The 12-point mPDAI score is calculated from two 6-point scales: 1) Clinical Symptoms: Stool Frequency (0=usual to postoperative stool frequency to 2=3 or more stools/day&gt;postoperative usual); Rectal bleeding (0=None or rare to 1=Present daily); Fecal urgency or abdominal cramps (0=None to 2=Usual), Fever [temperature &gt;37.8 degrees C] (0=Absent and 1=Present) for a clinical symptoms subscore of 0 (best) to 6 (worse); 2) Endoscopic Inflammation Findings: Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates and Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0 (best) to 6 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PDAI Remission at Weeks 14 and 34</measure>
    <time_frame>Weeks 14 and 34</time_frame>
    <description>Pouchitis Disease Activity Index (PDAI) remission is defined as PDAI score &lt;7 and a reduction of PDAI score by ≥3 points from Baseline. The 18-point PDAI score is calculated from three 6-point domain scales with total possible subscore of 0 (best) to 6 (worse): 1) Clinical Symptoms: Stool Frequency (0=usual to postoperative stool frequency to 2=3 or more stools/day&gt;postoperative usual); Rectal bleeding (0=None or rare,1=Present daily); Fecal urgency or abdominal cramps (0=None to 2=Usual), Fever [temperature &gt;37.8 degrees C] (0=Absent,1=Present); 2) Endoscopic Inflammation: Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates, Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0 (best) to 6 (worst); 3) Acute Histologic Inflammation: Polymorphic nuclear leukocyte infiltration (0=None to 3=Severe plus crypt abscess), Ulceration per low power field [mean] (0=0% to 3= &gt;50%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PDAI Remission</measure>
    <time_frame>Baseline up to Week 34</time_frame>
    <description>Time to remission is defined as the time in days from Baseline to PDAI Remission. PDAI Remission is defined as a PDAI score &lt;7 and a decrease in PDAI score of ≥3 points from Baseline. The 18-point PDAI score is calculated from three 6-point scales with total possible subscore of 0(best) to 6(worse):1)Clinical Symptoms: Stool Frequency(0=usual to postoperative stool frequency to 2=3 or more stools/day&gt;postoperative usual);Rectal bleeding(0=None or rare,1=Present daily);Fecal urgency or abdominal cramps(0=None to 2=Usual),Fever [temperature&gt;37.8 degrees C](0=Absent,1=Present);2) Endoscopic Inflammation:Edema,Granularity,Friability,Loss of vascular pattern,Mucous exudates,Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0(best) to 6(worst);3)Acute Histologic Inflammation:Polymorphic nuclear leukocyte infiltration(0=None to 3=Severe plus crypt abscess),Ulceration per low power field[mean](0=0% to 3= &gt;50%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Partial mPDAI Response at Weeks 14 and 34</measure>
    <time_frame>Weeks 14 and 34</time_frame>
    <description>Partial mPDAI response is defined as a reduction in mPDAI score by ≥2 points from Baseline. The 12-point mPDAI score is calculated from two 6-point scales: 1) Clinical Symptoms: Stool Frequency (0=usual to postoperative stool frequency to 2=3 or more stools/day&gt;postoperative usual); Rectal bleeding (0=None or rare to 1=Present daily); Fecal urgency or abdominal cramps (0=None to 2=Usual), Fever [temperature &gt;37.8 degrees C] (0=Absent and 1=Present) for a clinical symptoms subscore of 0 (best) to 6 (worse); 2) Endoscopic Inflammation Findings: Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates and Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0 (best) to 6 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PDAI Endoscopic Inflammation Subscore at Weeks 14 and 34</measure>
    <time_frame>Baseline up to Weeks 14 and 34</time_frame>
    <description>The PDAI Endoscopic Inflammation subscore is a sum of scores from findings for Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates, and Ulcerations, each scored on 0=not present to 1=present scale summed up to a subscore ranging from 0 (best) to 6 (worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PDAI Acute Histologic Inflammation Subscore at Weeks 14 and 34</measure>
    <time_frame>Baseline up to Weeks 14 and 34</time_frame>
    <description>The PDAI Acute Histologic Inflammation subscore is a sum score from findings for Polymorphic nuclear leukocyte infiltration (0=None to 3=Severe plus crypt abscess), and Ulceration per low power field [mean] (0=0% to 3= &gt;50%) summed up to a subscore ranging from 0 (best) to 6 (worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total PDAI Score at Weeks 14 and 34</measure>
    <time_frame>Baseline up to Weeks 14 and 34</time_frame>
    <description>The 18-point PDAI score is calculated from three 6-point domain scales with total possible subscore of 0 (best) to 6 (worse): 1) Clinical Symptoms: Stool Frequency (0=usual to postoperative stool frequency to 2=3 or more stools/day&gt;postoperative usual); Rectal bleeding (0=None or rare,1=Present daily); Fecal urgency or abdominal cramps (0=None to 2=Usual), Fever [temperature &gt;37.8 degrees C] (0=Absent,1=Present); 2) Endoscopic Inflammation: Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates, Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0 (best) to 6 (worst); 3) Acute Histologic Inflammation: Polymorphic nuclear leukocyte infiltration (0=None to 3=Severe plus crypt abscess), Ulceration per low power field [mean] (0=0% to 3= &gt;50%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Weeks 14, 22 and 34</measure>
    <time_frame>Baseline up to Weeks 14, 22 and 34</time_frame>
    <description>The IBDQ is an instrument used to assess quality of life in adult participants with inflammatory bowel disease (IBD). It includes 32 questions on 4 domains of Health-Related Quality-of-Life (HRQOL): Bowel Systems (10 items), Emotional Function (12 items), Social Function (5 items), and Systemic Function (5 items). Participants are asked to recall symptoms and quality of life from the last 2 weeks and rate each item on a 7-point Likert scale (1=worst to 7=best). A total IBDQ score is calculated by summing the scores from each domain; the total IBDQ score ranges from 32 to 224, with lower scores reflecting worse HRQOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cleveland Global Quality of Life (CGQL) at Weeks 14, 22 and 34</measure>
    <time_frame>Baseline up to Weeks 14, 22 and 34</time_frame>
    <description>The CGQL (Fazio score) is a quality-of-life indicator specifically for participants with ileal pouch-anal anastomosis. Participants rate 3 items (current quality of life, current quality of health, and current energy level), each on a scale of 0 to 10 (0=worst; 10=best). The scores are added, and the final CGQL utility score is obtained by dividing this result by 30.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Pouchitis</condition>
  <arm_group>
    <arm_group_label>Placebo IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vedolizumab placebo-matching intravenous (IV) infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vedolizumab IV 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vedolizumab 300 mg, IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vedolizumab Placebo</intervention_name>
    <description>Vedolizumab placebo-matching IV infusion</description>
    <arm_group_label>Placebo IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Ciprofloxacin tablets</description>
    <arm_group_label>Placebo IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vedolizumab</intervention_name>
    <description>Vedolizumab IV infusion</description>
    <arm_group_label>Vedolizumab IV 300 mg</arm_group_label>
    <other_name>Entyvio</other_name>
    <other_name>MLN0002 IV</other_name>
    <other_name>Kynteles</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. In the opinion of the investigator, the participant is capable of understanding and&#xD;
             complying with protocol requirements.&#xD;
&#xD;
          2. The participant or, when applicable, the participant's legally acceptable&#xD;
             representative signs and dates a written, informed consent form and any required&#xD;
             privacy authorization prior to the initiation of any study procedures.&#xD;
&#xD;
          3. Has a history of ileal pouch anal anastomosis (IPAA) for ulcerative colitis (UC)&#xD;
             completed at least 1 year prior to the Day 1 (Randomization) Visit.&#xD;
&#xD;
          4. Has pouchitis that is chronic or recurrent, defined by an modified pouchitis disease&#xD;
             activity index (mPDAI) score ≥5 assessed as average from 3 days immediately prior to&#xD;
             the Baseline endoscopy and a minimum endoscopic subscore of 2 (outside the staple or&#xD;
             suture line) with either (a) ≥3 recurrent episodes within 1 year prior to the&#xD;
             Screening Period treated with ≥2 weeks of antibiotic or other prescription therapy, or&#xD;
             (b) requiring maintenance antibiotic therapy taken continuously for ≥4 weeks&#xD;
             immediately prior to the Baseline Endoscopy Visit.&#xD;
&#xD;
          5. Agrees to take ciprofloxacin (500 mg twice daily) on Day 1 and through Week 4,&#xD;
             regardless of the previous treatment and to stop any previous antibiotic therapy on&#xD;
             Day 1 of the study (additional courses of antibiotics will be allowed, as needed, for&#xD;
             flares after Week 14).&#xD;
&#xD;
          6. A male participant who is nonsterilized and sexually active with a female partner of&#xD;
             childbearing potential agrees to use a barrier method of contraception (e.g., condom&#xD;
             with spermicide) from signing of informed consent throughout the duration of the study&#xD;
             and for 18 weeks after last dose. The female partner of a male participant should also&#xD;
             be advised to use a highly effective method of contraception.&#xD;
&#xD;
          7. A female participant of childbearing potential who is sexually active with a&#xD;
             nonsterilized male partner agrees to use a highly effective method of contraception&#xD;
             from signing of informed consent throughout the duration of the study and for 18 weeks&#xD;
             after last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Gastrointestinal Exclusion Criteria&#xD;
&#xD;
          1. Has Crohn's disease (CD), or CD of the pouch.&#xD;
&#xD;
          2. Has irritable pouch syndrome (IPS).&#xD;
&#xD;
          3. Has isolated or predominant cuffitis.&#xD;
&#xD;
          4. Has mechanical complications of the pouch (e.g., pouch stricture or pouch fistula).&#xD;
&#xD;
          5. Currently requires or has a planned surgical intervention for UC during the study.&#xD;
&#xD;
          6. Has diverting stoma.&#xD;
&#xD;
        Infectious Disease Exclusion Criteria 1. Has evidence of an active infection (e.g., sepsis,&#xD;
        cytomegalovirus, or listeriosis) during Screening.&#xD;
&#xD;
        2. Has active or latent tuberculosis (TB), regardless of treatment history, as evidenced by&#xD;
        any of the following:&#xD;
&#xD;
          1. A diagnostic TB test performed within 30 days of Screening or during the Screening&#xD;
             Period that is positive, as defined by:&#xD;
&#xD;
               1. A positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests. OR&#xD;
&#xD;
               2. A tuberculin skin test reaction ≥10 mm (≥5 mm in participants receiving the&#xD;
                  equivalent of &gt;15 mg/day prednisone).&#xD;
&#xD;
                  OR&#xD;
&#xD;
          2. Chest X-ray within 3 months prior to Day 1 that is suspicious for pulmonary TB, and a&#xD;
             positive or 2 successive indeterminate QuantiFERON test within 30 days prior to&#xD;
             Screening or during the Screening Period.&#xD;
&#xD;
             3. Has chronic hepatitis B virus (HBV) infection* or chronic hepatitis C virus (HCV)&#xD;
             infection** or a known history of human immunodeficiency virus (HIV) infection (or is&#xD;
             found to be seropositive at Screening) or participant is immunodeficient (e.g., due to&#xD;
             organ transplantation, history of common variable immunodeficiency, etc).&#xD;
&#xD;
             * Participants who are positive for hepatitis B virus surface antigen (HBsAg) will be&#xD;
             excluded. For participants who are negative for HBsAg but are positive for either&#xD;
             surface antibodies and/or core antibodies, HBV Deoxyribonucleic acid (DNA) polymerase&#xD;
             chain reaction will be performed and if any test result meets or exceeds detection&#xD;
             sensitivity, the participant will be excluded.&#xD;
&#xD;
               -  If participant is HCV antibody positive, then a viral load test will be&#xD;
                  performed. If the viral load test is positive then the participant will be&#xD;
                  excluded.&#xD;
&#xD;
                  4. Has evidence of active infection with Clostridium (C) difficile during&#xD;
                  Screening (to be confirmed by laboratory test)&#xD;
&#xD;
             General Exclusion Criteria&#xD;
&#xD;
               1. Has any prior exposure to vedolizumab, natalizumab, efalizumab, rituximab,&#xD;
                  etrolizumab, or anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1)&#xD;
                  therapy.&#xD;
&#xD;
               2. Has a history of hypersensitivity or allergies to vedolizumab or its components.&#xD;
&#xD;
               3. Has allergies to and/or contraindications for ciprofloxacin, a history of tendon&#xD;
                  disorders related to quinolone administration and/or glucose-6-phosphate&#xD;
                  dehydrogenase (G6PD) deficiency. Further conditions requiring precautions for use&#xD;
                  of ciprofloxacin have to be considered based on local prescribing information.&#xD;
&#xD;
               4. Is taking, has taken, or is required to take any excluded medications.&#xD;
&#xD;
               5. Has received any investigational or approved biologic or biosimilar agent within&#xD;
                  60 days prior to Randomization.&#xD;
&#xD;
               6. Has received an investigational nonbiologic therapy within 30 days prior to&#xD;
                  Randomization.&#xD;
&#xD;
               7. Has received an approved nonbiologic therapy (including 5-aminosalicylate&#xD;
                  [5-ASA], corticosteroid, azathioprine, 6-mercaptopurine [6-MP], etc.) in an&#xD;
                  investigational protocol within 30 days prior to Randomization.&#xD;
&#xD;
               8. Has received any live vaccinations within 30 days prior to randomization.&#xD;
&#xD;
               9. Has a positive progressive multifocal leukoencephalopathy (PML) subjective&#xD;
                  symptom checklist at Screening.&#xD;
&#xD;
              10. Has had a kidney, heart, or lung transplant.&#xD;
&#xD;
              11. Has a history of malignancy, except for the following: adequately-treated&#xD;
                  non-metastatic basal cell skin cancer; squamous cell skin cancer that has been&#xD;
                  adequately treated and that has not recurred for at least 1 year prior to the&#xD;
                  Screening visit; and history of cervical carcinoma in situ that has been&#xD;
                  adequately treated and that has not recurred for at least 3 years prior to&#xD;
                  Screening. Participants with a remote history of malignancy (e.g., &gt;10 years&#xD;
                  since completion of curative therapy without recurrence) will be considered based&#xD;
                  on the nature of the malignancy and the therapy received and must be discussed&#xD;
                  with the sponsor on a case-by-case basis prior to enrollment.&#xD;
&#xD;
              12. Has a history of any major neurological disorders, including stroke, multiple&#xD;
                  sclerosis, brain tumor, demyelinating, or neurodegenerative disease.&#xD;
&#xD;
              13. Has conditions, which in the opinion of the investigator, may interfere with the&#xD;
                  participant's ability to comply with the study procedures.&#xD;
&#xD;
              14. Has any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal,&#xD;
                  gastrointestinal (GI), genitourinary, hematological, coagulation, immunological,&#xD;
                  endocrine/metabolic, neurologic, or other medical disorder that, in the opinion&#xD;
                  of the investigator, would confound the study results or compromise participant&#xD;
                  safety.&#xD;
&#xD;
              15. Has any of the following laboratory abnormalities during the Screening Period:&#xD;
&#xD;
               1. Hemoglobin level &lt;8 g/dL.&#xD;
&#xD;
               2. White blood cell (WBC) count &lt;3 × 10^9/L.&#xD;
&#xD;
               3. Lymphocyte count &lt;0.5 × 10^9/L.&#xD;
&#xD;
               4. Platelet count &lt;100 × 10^9/L or &gt;1200 × 10^9/L.&#xD;
&#xD;
               5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;3 × the upper&#xD;
                  limit of normal (ULN).&#xD;
&#xD;
               6. Alkaline phosphatase &gt;3 × ULN.&#xD;
&#xD;
               7. Serum creatinine &gt;2 × ULN.&#xD;
&#xD;
             16. If female, the participant is pregnant or lactating or intending to become&#xD;
             pregnant or nurse before, during, or within 18 weeks after the last dose of study&#xD;
             medication; or intending to donate ova during such time period.&#xD;
&#xD;
             17. If male, the participant intends to donate sperm or father a child during the&#xD;
             course of this study or for 18 weeks after the last dose of study medication.&#xD;
&#xD;
             18. Is an immediate family member, study site employee, or is in a dependent&#xD;
             relationship with a study site employee who is involved in conduct of this study&#xD;
             (e.g., spouse, parent, child, sibling) or may consent under duress.&#xD;
&#xD;
             19. Has a history of drug abuse (defined as any illicit drug use) or a history of&#xD;
             alcohol abuse within 1 year prior to Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina GI</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas HealthCare System Digestive Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-1375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - University Hospital Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GIRI (GI Research Institute)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hopital de Pontchaillou</name>
      <address>
        <city>Rennes cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne - Hopital Nord</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hopital Rangueil</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy Hopital de Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin -Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Hospital Hamburg - West</name>
      <address>
        <city>Hamburg</city>
        <zip>22559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis fuer Gastroenterologie, Drs. Ehehalt/ Helmstaedter</name>
      <address>
        <city>Heidelberg</city>
        <zip>69121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim GmbH Universitaetsklinikum</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas IRCCS</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doctor Negrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mark's Hospital</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 2EF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <results_first_submitted>June 9, 2021</results_first_submitted>
  <results_first_submitted_qc>June 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2021</results_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pouchitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Vedolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02790138/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02790138/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 31 investigative sites in Canada, United States, Belgium, France, Germany, Italy, Netherlands, Spain, and United Kingdom from 12 October 2016 to 2 February 2021. Data is reported for primary outcome measures up to 11 June 2020.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of chronic or recurrent pouchitis were enrolled in a 1:1 ratio to receive placebo IV or vedolizumab IV 300 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo IV</title>
          <description>Vedolizumab placebo-matching intravenous (IV) infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.</description>
        </group>
        <group group_id="P2">
          <title>Vedolizumab IV 300 mg</title>
          <description>Vedolizumab 300 mg, IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Significant Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set included all randomized participants who received at least 1 dose of study medication, as randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo IV</title>
          <description>Vedolizumab placebo-matching IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.</description>
        </group>
        <group group_id="B2">
          <title>Vedolizumab IV 300 mg</title>
          <description>Vedolizumab 300 mg, IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" spread="13.48"/>
                    <measurement group_id="B2" value="40.8" spread="11.32"/>
                    <measurement group_id="B3" value="41.9" spread="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175.3" spread="9.10"/>
                    <measurement group_id="B2" value="172.4" spread="10.79"/>
                    <measurement group_id="B3" value="173.8" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.60" spread="19.115"/>
                    <measurement group_id="B2" value="72.13" spread="17.588"/>
                    <measurement group_id="B3" value="75.87" spread="18.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI = weight (kg)/[height (m)^2</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.74" spread="5.125"/>
                    <measurement group_id="B2" value="24.13" spread="4.891"/>
                    <measurement group_id="B3" value="24.93" spread="5.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Chronic or Recurrent Pouchitis Achieving Clinically Relevant Remission at Week 14</title>
        <description>Clinically relevant remission is defined as modified Pouchitis Disease Activity Index (mPDAI) score &lt;5 and a reduction of mPDAI score by ≥2 points from Baseline. The 12-point mPDAI score is calculated from two 6-point subscales: 1) Clinical Symptoms: Stool Frequency (0=usual to postoperative stool frequency to 2=three or more stools/day&gt;postoperative usual); Rectal bleeding (0=None or rare to 1=Present daily); Fecal urgency or abdominal cramps (0=None to 2=Usual), Fever [temperature &gt;37.8 degrees C] (0=Absent and 1=Present) for a clinical symptoms subscore of 0 (best) to 6 (worse); 2) Endoscopic Inflammation Findings: Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates and Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0 (best) to 6 (worst).</description>
        <time_frame>Week 14</time_frame>
        <population>Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study medication, as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo IV</title>
            <description>Vedolizumab placebo-matching IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.</description>
          </group>
          <group group_id="O2">
            <title>Vedolizumab IV 300 mg</title>
            <description>Vedolizumab 300 mg, IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Chronic or Recurrent Pouchitis Achieving Clinically Relevant Remission at Week 14</title>
          <description>Clinically relevant remission is defined as modified Pouchitis Disease Activity Index (mPDAI) score &lt;5 and a reduction of mPDAI score by ≥2 points from Baseline. The 12-point mPDAI score is calculated from two 6-point subscales: 1) Clinical Symptoms: Stool Frequency (0=usual to postoperative stool frequency to 2=three or more stools/day&gt;postoperative usual); Rectal bleeding (0=None or rare to 1=Present daily); Fecal urgency or abdominal cramps (0=None to 2=Usual), Fever [temperature &gt;37.8 degrees C] (0=Absent and 1=Present) for a clinical symptoms subscore of 0 (best) to 6 (worse); 2) Endoscopic Inflammation Findings: Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates and Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0 (best) to 6 (worst).</description>
          <population>Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study medication, as randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="3.3" upper_limit="21.4"/>
                    <measurement group_id="O2" value="31.4" lower_limit="19.1" upper_limit="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>The significance level was 0.05.</p_value_desc>
            <method>Fisher's Exact Test</method>
            <param_type>Percentage Difference</param_type>
            <param_value>21.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.9</ci_lower_limit>
            <ci_upper_limit>37.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Chronic or Recurrent Pouchitis Achieving Clinically Relevant Remission at Week 34</title>
        <description>Clinically relevant remission is defined as mPDAI score &lt;5 and a reduction of mPDAI score by ≥2 points from Baseline. The 12-point mPDAI score is calculated from two 6-point scales: 1) Clinical Symptoms: Stool Frequency (0=usual to postoperative stool frequency to 2=3 or more stools/day&gt;postoperative usual); Rectal bleeding (0=None or rare to 1=Present daily); Fecal urgency or abdominal cramps (0=None to 2=Usual), Fever [temperature &gt;37.8 degrees C] (0=Absent and 1=Present) for a clinical symptoms subscore of 0 (best) to 6 (worse); 2) Endoscopic Inflammation Findings: Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates and Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0 (best) to 6 (worst).</description>
        <time_frame>Week 34</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PDAI Remission at Weeks 14 and 34</title>
        <description>Pouchitis Disease Activity Index (PDAI) remission is defined as PDAI score &lt;7 and a reduction of PDAI score by ≥3 points from Baseline. The 18-point PDAI score is calculated from three 6-point domain scales with total possible subscore of 0 (best) to 6 (worse): 1) Clinical Symptoms: Stool Frequency (0=usual to postoperative stool frequency to 2=3 or more stools/day&gt;postoperative usual); Rectal bleeding (0=None or rare,1=Present daily); Fecal urgency or abdominal cramps (0=None to 2=Usual), Fever [temperature &gt;37.8 degrees C] (0=Absent,1=Present); 2) Endoscopic Inflammation: Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates, Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0 (best) to 6 (worst); 3) Acute Histologic Inflammation: Polymorphic nuclear leukocyte infiltration (0=None to 3=Severe plus crypt abscess), Ulceration per low power field [mean] (0=0% to 3= &gt;50%).</description>
        <time_frame>Weeks 14 and 34</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PDAI Remission</title>
        <description>Time to remission is defined as the time in days from Baseline to PDAI Remission. PDAI Remission is defined as a PDAI score &lt;7 and a decrease in PDAI score of ≥3 points from Baseline. The 18-point PDAI score is calculated from three 6-point scales with total possible subscore of 0(best) to 6(worse):1)Clinical Symptoms: Stool Frequency(0=usual to postoperative stool frequency to 2=3 or more stools/day&gt;postoperative usual);Rectal bleeding(0=None or rare,1=Present daily);Fecal urgency or abdominal cramps(0=None to 2=Usual),Fever [temperature&gt;37.8 degrees C](0=Absent,1=Present);2) Endoscopic Inflammation:Edema,Granularity,Friability,Loss of vascular pattern,Mucous exudates,Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0(best) to 6(worst);3)Acute Histologic Inflammation:Polymorphic nuclear leukocyte infiltration(0=None to 3=Severe plus crypt abscess),Ulceration per low power field[mean](0=0% to 3= &gt;50%).</description>
        <time_frame>Baseline up to Week 34</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Partial mPDAI Response at Weeks 14 and 34</title>
        <description>Partial mPDAI response is defined as a reduction in mPDAI score by ≥2 points from Baseline. The 12-point mPDAI score is calculated from two 6-point scales: 1) Clinical Symptoms: Stool Frequency (0=usual to postoperative stool frequency to 2=3 or more stools/day&gt;postoperative usual); Rectal bleeding (0=None or rare to 1=Present daily); Fecal urgency or abdominal cramps (0=None to 2=Usual), Fever [temperature &gt;37.8 degrees C] (0=Absent and 1=Present) for a clinical symptoms subscore of 0 (best) to 6 (worse); 2) Endoscopic Inflammation Findings: Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates and Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0 (best) to 6 (worst).</description>
        <time_frame>Weeks 14 and 34</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PDAI Endoscopic Inflammation Subscore at Weeks 14 and 34</title>
        <description>The PDAI Endoscopic Inflammation subscore is a sum of scores from findings for Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates, and Ulcerations, each scored on 0=not present to 1=present scale summed up to a subscore ranging from 0 (best) to 6 (worse).</description>
        <time_frame>Baseline up to Weeks 14 and 34</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PDAI Acute Histologic Inflammation Subscore at Weeks 14 and 34</title>
        <description>The PDAI Acute Histologic Inflammation subscore is a sum score from findings for Polymorphic nuclear leukocyte infiltration (0=None to 3=Severe plus crypt abscess), and Ulceration per low power field [mean] (0=0% to 3= &gt;50%) summed up to a subscore ranging from 0 (best) to 6 (worse).</description>
        <time_frame>Baseline up to Weeks 14 and 34</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total PDAI Score at Weeks 14 and 34</title>
        <description>The 18-point PDAI score is calculated from three 6-point domain scales with total possible subscore of 0 (best) to 6 (worse): 1) Clinical Symptoms: Stool Frequency (0=usual to postoperative stool frequency to 2=3 or more stools/day&gt;postoperative usual); Rectal bleeding (0=None or rare,1=Present daily); Fecal urgency or abdominal cramps (0=None to 2=Usual), Fever [temperature &gt;37.8 degrees C] (0=Absent,1=Present); 2) Endoscopic Inflammation: Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates, Ulcerations. Each item is scored on a scale of 0=not present to 1=present summed up to an endoscopic subscore ranging from 0 (best) to 6 (worst); 3) Acute Histologic Inflammation: Polymorphic nuclear leukocyte infiltration (0=None to 3=Severe plus crypt abscess), Ulceration per low power field [mean] (0=0% to 3= &gt;50%).</description>
        <time_frame>Baseline up to Weeks 14 and 34</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Weeks 14, 22 and 34</title>
        <description>The IBDQ is an instrument used to assess quality of life in adult participants with inflammatory bowel disease (IBD). It includes 32 questions on 4 domains of Health-Related Quality-of-Life (HRQOL): Bowel Systems (10 items), Emotional Function (12 items), Social Function (5 items), and Systemic Function (5 items). Participants are asked to recall symptoms and quality of life from the last 2 weeks and rate each item on a 7-point Likert scale (1=worst to 7=best). A total IBDQ score is calculated by summing the scores from each domain; the total IBDQ score ranges from 32 to 224, with lower scores reflecting worse HRQOL.</description>
        <time_frame>Baseline up to Weeks 14, 22 and 34</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cleveland Global Quality of Life (CGQL) at Weeks 14, 22 and 34</title>
        <description>The CGQL (Fazio score) is a quality-of-life indicator specifically for participants with ileal pouch-anal anastomosis. Participants rate 3 items (current quality of life, current quality of health, and current energy level), each on a scale of 0 to 10 (0=worst; 10=best). The scores are added, and the final CGQL utility score is obtained by dividing this result by 30.</description>
        <time_frame>Baseline up to Weeks 14, 22 and 34</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug up to 18 weeks after last dose (Up to 50 weeks).</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo IV</title>
          <description>Vedolizumab placebo-matching IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.</description>
        </group>
        <group group_id="E2">
          <title>Vedolizumab IV 300 mg</title>
          <description>Vedolizumab 300 mg, IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pouchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pouchitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>TrialDisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

